CAS 1118567-05-7

Bexagliflozin

CAS: 1118567-05-7

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Formel: C₂₄H₂₉ClO₇

Reinheit: 98%

Molekulargewicht: 464.94

Ref: IN-DG629906

EGT1442

CAS: 1118567-05-7

Formel: C₂₄H₂₉ClO₇

Reinheit: 99%

Farbe und Form: Solid

Molekulargewicht: 464.9359

Ref: IN-DA008TOL

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin

Formel: C₂₄H₂₉ClO₇

Reinheit: ≥98%

Molekulargewicht: 464.94

Ref: 54-BUP03804

Bexagliflozin

CAS: 1118567-05-7

Formel: C₂₄H₂₉ClO₇

Molekulargewicht: 464.94

Ref: 4Z-B-295001

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 2 nM for human SGLT2.

Formel: C₂₄H₂₉ClO₇

Reinheit: 98.99% - 99.89%

Farbe und Form: Solid

Molekulargewicht: 464.94

Ref: TM-T7217

Bexagliflozin

Kontrolliertes Produkt

CAS: 1118567-05-7

Formel: C₂₄H₂₉ClO₇

Farbe und Form: Neat

Molekulargewicht: 464.94

Ref: TR-B336785

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin is a drug that is used to treat type II diabetes in adults. It helps to control blood sugar levels by inhibiting the enzyme DPP-IV and increasing insulin release from the pancreas. Bexagliflozin has been shown to be effective in lowering blood sugar levels in patients with chronic kidney disease and cancer, as well as those with a body mass index (BMI) of 30 or higher. This drug is an oral hypoglycaemic agent that can be used for diagnostic purposes. It has also been shown to be clinically effective for the treatment of diabetic nephropathy and diabetic retinopathy. The enantiomers of bexagliflozin can be differentiated according to their pharmacological properties, which may allow for more targeted therapy.

Formel: C₂₄H₂₉ClO₇

Reinheit: Min. 95%

Molekulargewicht: 464.94 g/mol

Ref: 3D-FA145137

Bexagliflozin

CAS: 1118567-05-7

Formel: C₂₄H₂₉ClO₇

Molekulargewicht: 464.94

Ref: ST-EA-CP-B168000